Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD), a Delaware corporation, filed this Form 8-K on February 18, 2020. The report details the closing of the Company's initial public offering (IPO) and the concurrent adoption of amended and restated corporate governance documents.
Key Financial Metrics
- Capital Raised: The Company sold 16,100,000 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 2,100,000 shares.
- Offering Price: $17.00 per share.
- Gross Proceeds: $273.7 million (before deducting underwriting discounts, commissions, and estimated offering expenses).
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, or debt figures for the reporting period.
Material Changes
The primary material change reported is the transition from a private to a public company via the IPO closing on February 18, 2020. Additionally, the Company amended and restated its Certificate of Incorporation and Bylaws effective immediately prior to the IPO closing to align with public company requirements.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard incorporation of the Prospectus by reference. The document focuses strictly on the mechanics of the IPO closing and corporate governance updates.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses by reviewing the final Prospectus.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific governance provisions.
- Confirm the lock-up period details and any restrictions on share sales for existing shareholders as outlined in the IPO underwriting agreement.